Renal Cell Carcinoma

Molecular Biology, Immunology, and Clinical Management

  • Ronald M. Bukowski
  • Andrew C. Novick

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. Joshua E. Muscat
      Pages 3-13
    3. Howard S. Levin, Jonathan L. Myles
      Pages 15-38
    4. James H. Finke, Lisa Salvucci Kierstead, Elena Ranieri, Walter J. Storkus
      Pages 39-62
    5. Robert G. Uzzo, Patricia Rayman, Andrew C. Novick, Ronald M. Bukowski, James H. Finke
      Pages 63-78
    6. Erik Enquist, Norman Zambrano, Burton Zbar, W. Marston Linehan, McClellan M. Walther
      Pages 79-92
    7. Evan B. Cohn, Steven C. Campbell
      Pages 93-110
    8. Joel W. Slaton, David A. Swanson
      Pages 111-134
    9. Riyadh Aldaabil, David Peereboom
      Pages 135-145
  3. Management of Localized Renal Cell Carcinoma

    1. Front Matter
      Pages 161-161
    2. Chad W. M. Ritenour, Fray F. Marshall
      Pages 173-187
    3. Inderbir S. Gill
      Pages 189-202
    4. Ronald M. Bukowski
      Pages 203-212
  4. Management of Advanced and/or Metastatic Renal Cell Carcinoma

    1. Front Matter
      Pages 213-213
    2. Javier A. Ruiz, Haralambos Raftopoulos, Daniel P. Petrylak
      Pages 283-300
    3. Thomas Olencki, Ronald M. Bukowski
      Pages 301-318
    4. Robert J. Motzer, William J. Berg
      Pages 319-329
    5. Jens Atzpodien, J. Janssen, J. Buer, S. Sel, K. Oevermann
      Pages 331-341
    6. Egbert Oosterwijk, Chetan R. Divgi, Martijn S. Steffens, Neil H. Bander
      Pages 343-358
    7. Barbara J. Gitlitz, Arie S. Belldegrun, Robert A. Figlin
      Pages 359-379
    8. Kevin R. Bigelow, Michael T. Spiotto, Walter M. Stadler
      Pages 381-395
  5. Back Matter
    Pages 425-434

About this book


Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled.


Staging adjuvant therapy cancer carcinoma cell epidemiology genetics immunotherapy interferon metastatic disease molecular genetics renal cell carcinoma screening surgery tumor

Editors and affiliations

  • Ronald M. Bukowski
    • 1
  • Andrew C. Novick
    • 2
  1. 1.Experimental TherapeuticsCleveland Clinic Taussig Cancer CenterClevelandUSA
  2. 2.Department of UrologyCleveland Clinic FoundationClevelandUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology